Skip to navigation Skip to content

Myelodysplastic syndrome Program in Pharmaceutical Benefits Scheme (PBS) 012-18051125

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised azacitidine, decitabine+cedazuridine and lenalidomide for patients with myelodysplastic syndrome (MDS).

Myelodysplastic syndrome and listing dates

Myelodysplastic syndromes (MDS) are a group of disorders caused by poorly formed or dysfunctional blood cells.

Listing dates are:

  • azacitidine – 1 February 2011
  • lenalidomide – 1 October 2013
  • decitabine+cedazuridine – 1 October 2022

For more information, see Written Authority Required for Drugs.

Enquiries

  • Transfer enquiries about prescription arrangements for azacitidine and lenalidomide to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated
  • Transfer enquiries about prescription arrangements for decitabine+cedazuridine to PBS authority approvals

The Resources page contains links to application forms, contact details, item and restriction codes, the PBS schedule and the Services Australia website.

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs